Published in J Med Chem on November 23, 2013
Targeting histone lysine demethylases - progress, challenges, and the future. Biochim Biophys Acta (2014) 1.01
Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res (2014) 0.96
Docking Screens for Novel Ligands Conferring New Biology. J Med Chem (2016) 0.90
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol (2016) 0.85
KDM1 class flavin-dependent protein lysine demethylases. Biopolymers (2015) 0.84
Novel mycosin protease MycP₁ inhibitors identified by virtual screening and 4D fingerprints. J Chem Inf Model (2014) 0.83
Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. BMC Cancer (2014) 0.83
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol (2016) 0.83
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. J Med Chem (2015) 0.80
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget (2016) 0.78
High-throughput screening to identify inhibitors of lysine demethylases. Epigenomics (2015) 0.78
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. ACS Med Chem Lett (2014) 0.76
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis (2016) 0.75
Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. Bioorg Med Chem (2016) 0.75
Downregulation of LSD1 suppresses the proliferation, tumorigenicity and invasion of papillary thyroid carcinoma K1 cells. Oncol Lett (2016) 0.75
SUMOylation Regulates Growth Factor Independence 1 in Transcriptional Control and Hematopoiesis. Mol Cell Biol (2016) 0.75
Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors. ACS Med Chem Lett (2017) 0.75
Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1. PLoS One (2017) 0.75
Rapid activity prediction of HIV-1 integrase inhibitors: harnessing docking energetic components for empirical scoring by chemometric and artificial neural network approaches. J Comput Aided Mol Des (2016) 0.75
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A (2002) 9.60
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2006) 2.33
Targeting Axl and Mer kinases in cancer. Mol Cancer Ther (2011) 1.88
Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc (2002) 1.82
Diagnosis of common mental disorders by using PRIME-MD Patient Health Questionnaire. Indian J Med Res (2008) 1.81
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
The efficacy of pregabalin for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled double-blind study. J Anesth (2014) 1.56
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol (2002) 1.50
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Chlorhexidine to maintain cleanliness of laryngoscope handles: an audit and laboratory study. Eur J Anaesthesiol (2013) 1.46
Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J Am Chem Soc (2005) 1.40
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.31
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol (2002) 1.24
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther (2014) 1.18
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.17
Telomere inhibition and telomere disruption as processes for drug targeting. Annu Rev Pharmacol Toxicol (2002) 1.17
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2007) 1.15
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol Cancer Ther (2003) 1.14
Telomeres and telomerases as drug targets. Curr Opin Pharmacol (2002) 1.14
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) (2012) 1.13
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol (2005) 1.13
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol (2003) 1.12
Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol (2012) 1.02
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res (2007) 1.01
Laparoscopic right hemicolectomy with transvaginal colon extraction using a laparoscopic posterior colpotomy: a 2-year series from a single institution. Surg Laparosc Endosc Percutan Tech (2011) 1.00
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res (2007) 0.99
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol (2011) 0.98
Antidiabetic and antioxidant potential of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced type-2 diabetes mellitus (T2DM) rats. J Ethnopharmacol (2012) 0.97
Retracted Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A (2004) 0.97
Overview for various aspects of the health benefits of Piper longum linn. fruit. J Acupunct Meridian Stud (2011) 0.97
Colon cancer. J Natl Compr Canc Netw (2011) 0.96
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 0.96
Intrinsic third ventricular craniopharyngiomas: report on six cases and a review of the literature. Surg Neurol (2003) 0.96
Spatially fractionated radiation induces cytotoxicity and changes in gene expression in bystander and radiation adjacent murine carcinoma cells. Radiat Res (2012) 0.96
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 0.94
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther (2002) 0.94
Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS One (2013) 0.93
Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett (2011) 0.93
Laminin-5 beta3A expression in LNCaP human prostate carcinoma cells increases cell migration and tumorigenicity. Neoplasia (2004) 0.92
Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis--a preliminary report. Indian J Gastroenterol (2004) 0.92
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs (2014) 0.90
Activators of PKM2 in cancer metabolism. Future Med Chem (2014) 0.89
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemother Pharmacol (2014) 0.87
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res (2013) 0.87
Effects of late administration of pentoxifylline and tocotrienols in an image-guided rat model of localized heart irradiation. PLoS One (2013) 0.85
GC-MS analysis and screening of antidiabetic, antioxidant and hypolipidemic potential of Cinnamomum tamala oil in streptozotocin induced diabetes mellitus in rats. Cardiovasc Diabetol (2012) 0.85
Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity. Mol Cancer Ther (2005) 0.85
Education effects on the International HIV Dementia Scale. J Neurovirol (2010) 0.85
Genome-wide profiling of human cap-independent translation-enhancing elements. Nat Methods (2013) 0.84
Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Gaza Strip Palestinians. Blood Cells Mol Dis (2012) 0.84
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther (2006) 0.84
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther (2003) 0.84
Chemical genetic screen reveals a role for desmosomal adhesion in mammary branching morphogenesis. J Biol Chem (2012) 0.84
Structure of a quinobenzoxazine--G-quadruplex complex by REDOR NMR. Biochemistry (2004) 0.84
Antiulcer effect of the methanolic extract of Tamarindus indica seeds in different experimental models. J Pharm Bioallied Sci (2011) 0.84
In vitro evaluation of antimicrobial and antioxidant activities of methanolic extract of Jasminum humile leaves. Asian Pac J Trop Med (2011) 0.84
Elizabethkingia meningosepticum : An Emerging Cause of Septicemia in Critically III Patients. J Lab Physicians (2011) 0.84
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.83
Aerophagia may not cause gastroesophageal reflux. J Clin Sleep Med (2013) 0.83
Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. BMC Cancer (2014) 0.83
Structure-based design of novel anti-cancer agents targeting aurora kinases. Curr Med Chem Anticancer Agents (2003) 0.82
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol (2009) 0.82
Comparative study of the experience of caregiving in bipolar affective disorder and schizophrenia. Int J Soc Psychiatry (2011) 0.82
TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res (2013) 0.82
Wilson's disease presenting as haemolytic anaemia. J Assoc Physicians India (2009) 0.82
Antiulcer potential of the ethanolic extract of Aerva persica Merrill root in rats. J Acupunct Meridian Stud (2012) 0.81
Neuropsychological test performance among healthy persons in northern India: development of normative data. J Neurovirol (2015) 0.81
Beryllium induces premature senescence in human fibroblasts. J Pharmacol Exp Ther (2007) 0.81
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res (2011) 0.80
Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice. Pancreas (2008) 0.80
p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors. Mol Cancer Ther (2003) 0.80
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol (2014) 0.80
Slipped capital femoral epiphysis in children aged less than 10 years. J Pediatr Orthop B (2010) 0.80
In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol (2010) 0.79
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol (2005) 0.79